Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
307
Views
0
CrossRef citations to date
0
Altmetric
Letters to Editor

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

Alba Cabirtaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7198-8894
ORCID Icon,
Gloria Hidalgo-Gómeza Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainORCID Iconhttps://orcid.org/0000-0003-3599-1724
ORCID Icon,
Ana Marín-Nieblaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainORCID Iconhttps://orcid.org/0000-0002-7592-6815
ORCID Icon,
Laura Gallura Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
,
Silvia Saumella Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainORCID Iconhttps://orcid.org/0000-0001-8635-4376
ORCID Icon,
Josep Castellvíc Department of Pathology, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-5745-9996
ORCID Icon,
Eva Cataláa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainORCID Iconhttps://orcid.org/0000-0003-3478-9110
ORCID Icon,
Adoración Blancoa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
,
Laura López-Andreonia Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
,
María Julia Montoroa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainORCID Iconhttps://orcid.org/0000-0001-9532-7417
ORCID Icon,
Mayda Navarretea Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
,
Carlos Palacio-Garcíaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, SpainORCID Iconhttps://orcid.org/0000-0002-9085-3327
ORCID Icon,
Bárbara Tazón-Vegaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
,
Sabela Bobilloa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
,
Francesc Boscha Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
&
Margarita Ortegaa Department of Hematology, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-1985-3965
ORCID Icon show all
Pages 1746-1749 | Received 18 Nov 2021, Accepted 18 Jan 2022, Published online: 07 Feb 2022

References

  • Epperla N, Hamadani M, Fenske TS, et al. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703–706.
  • Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82(3):567–575.
  • Schieber M, Gordon LI, Karmali R. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018;7:1136. Published 2018 Jul 25.
  • Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–1656.
  • Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408–1418.
  • Roué G, Sola B. Management of drug resistance in mantle cell lymphoma. Cancers (Basel). 2020;12;12(6):1565.
  • Wlodarska I, Meeus P, Stul M, et al. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia. 2004;18(10):1705–1710.
  • Komatsu H, Yoshida K, Seto M, et al. Overexpression of PRAD1 in a mantle zone lymphoma patient with a t(11;22)(q13;q11) translocation. Br J Haematol. 1993;85(2):427–429.
  • Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood. 1994;84(4):1226–1231.
  • Espinet B, Salaverria I, Beà S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49(5):439–451.
  • Rocha CK, Praulich I, Gehrke I, et al. A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report. Mol Cytogenet. 2011;4(1):8.
  • Marrero WD, Cruz-Chacón A, Cabanillas F. Mantle cell lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant? Leuk Lymphoma. 2018;59(10):2509–2511.
  • Maekawa F, Kishimori C, Nakagawa M, et al. Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma. Blood Adv. 2021;5(1):61–65.
  • Woroniecka R, Grygalewicz B, Pienkowska-Grela B, et al. Variant t(2;11)(p11.2;q13) without IGK involvement in a case of mantle cell lymphoma. Cancer Genet Cytogenet. 2007;175(2):154–158.
  • Beekman R, Amador V, Campo E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. 2018;25(4):299–306.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.